logo
Plus   Neg
Share
Email

Stock To Watch: Intellia Therapeutics Inc. (NTLA)

Shares of Intellia Therapeutics Inc. (NTLA) were down 3.68% and closed Friday's trading session at $13.62. In the pre-market session today, the stock is currently trading at $13.82, up 20 cents or 1.47%. The stock has been trading in a range of $10.26 - $19.00 in the past one year.

Today, Intellia is presenting new data from two of its development programs at Keystone Symposia's Engineering the Genome Conference, a joint meeting with the Emerging Cellular Therapies: Cancer and Beyond Conference, taking place Feb. 8-12, 2020, in Banff, Canada.

Intellia researchers are presenting data in support of the company's lead engineered cell therapy development candidate, NTLA-5001 for the treatment of the hematological cancer, acute myeloid leukemia (AML). Intellia also is sharing preclinical results for its hereditary angioedema (HAE) program, which is Intellia's third CRISPR/Cas9 development program, announced in January 2020.

"Intellia continues to demonstrate strong progress across both our engineered cell therapy and in vivo pipelines," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are observing very favorable preclinical data with our engineered T cells, and we are moving ahead with IND-enabling studies and manufacturing for NTLA-5001, to enable a regulatory submission in the first half of 2021..."

The data being presented at the Keystone conference substantiate the advantages that a homogeneous T cell product developed through CRISPR engineering, like NTLA-5001, may have over traditional T cell engineering approaches.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
Follow RTT